2018
Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance
Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget 2018, 9: 21359-21365. PMID: 29765545, PMCID: PMC5940363, DOI: 10.18632/oncotarget.25103.Peer-Reviewed Original ResearchLow-risk prostate cancerProstate cancerWhite American menActive surveillanceAfrican American menRacial disparitiesRadical prostatectomyProstate cancer active surveillanceActive surveillance eligibilityMulti-institution databaseRisk prostate cancerUnderwent radical prostatectomyActive surveillance criteriaPositive surgical marginsTertiary care institutionSingle-institution studyMulti-institution analysisPotential racial disparitiesSignificant racial disparitiesPercentage cancerOncologic outcomesSurgical marginsHigher BMIProspective studyCancer outcomes
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsNeutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer
Kwon Y, Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: e1-e8. PMID: 26341038, PMCID: PMC5767465, DOI: 10.1016/j.clgc.2015.07.018.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerAbsolute lymphocyte countAbsolute neutrophil countLow-risk prostate cancer patientsProstate cancer patientsProstate cancerLymphocyte countANC groupLymphocyte ratioBiochemical recurrenceCancer patientsActive surveillanceHigher prostate-specific antigen levelMetastatic castration-resistant prostate cancerLow-risk PCa patientsProstate-specific antigen levelHigh absolute lymphocyte countCastration-resistant prostate cancerBiochemical recurrence-free survivalRobot-assisted radical prostatectomyAdverse pathologic outcomesAppropriate patient selectionKaplan-Meier methodRecurrence-free survivalRisk stratification toolPathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyRadical prostatectomyActive surveillanceAdvanced diseaseUnderwent robot-assisted radical prostatectomyLow-risk prostate cancerLower prostate volumePSA density levelsLow-risk diseaseActive surveillance cohortOrgan-confined diseaseSpecimens of patientsAdvanced pathologic featuresProspective cohortAdditional patientsPathologic featuresPathologic findingsProstate volumeSingle centerProspective studyGleason scoreSurveillance cohortDefinitive interventionClinicopathological resultsPathologic analysis
2014
MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA
Ha Y, Patel N, Salmasi A, Singer E, Yu J, Kim J, Kim W, Kim I. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA. Journal Of Urology 2014, 191: e821. DOI: 10.1016/j.juro.2014.02.2235.Peer-Reviewed Original Research
2013
Active surveillance in men with low-risk prostate cancer: current and future challenges.
Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.Peer-Reviewed Original ResearchLow-risk prostate cancerActive surveillanceProstate cancerSurvival rateCancer-specific survival ratesProstate-specific antigen (PSA) screeningActive surveillance protocolsCost of overtreatmentActive surveillance programPSA kineticsAntigen screeningSurveillance protocolInstitutional protocolEligibility criteriaMortality rateNew biomarkersCancerSurveillance programLong-term studiesTreatment triggersInterventionMenGenetic testsSurveillanceContemporary review226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE
Ha Y, Salmasi A, Kim J, Joung J, Lee D, Kim W, Kim I. 226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE. Journal Of Urology 2013, 189: e93. DOI: 10.1016/j.juro.2013.02.1606.Peer-Reviewed Original ResearchIncreased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance
Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkAA menRadical prostatectomyActive surveillanceProstate cancerNCCN criteriaBiopsy coresAS criteriaAS inclusion criteriaFinal surgical pathologyComprehensive Cancer NetworkPositive biopsy coresDatabase of menWorse clinicopathological featuresAfrican American menPathological upstagingAdvanced diseaseIndependent predictorsPathologic characteristicsClinicopathological featuresPreoperative PSAClinicopathologic findingsWA patientsInclusion criteriaPositive coresIncidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance
Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance. Urologia Internationalis 2013, 90: 301-305. PMID: 23391718, DOI: 10.1159/000345292.Peer-Reviewed Original ResearchConceptsGleason score 3Prostate cancerRadical prostatectomyActive surveillanceScore 3Positive coresIncidence of upstagingPrediction of upgradingPSA cutoff levelPreoperative PSA levelUpstaging ratePSA levelsCancer involvementClinical stageNeedle biopsyUpstagingPatientsCutoff levelBiopsyMarginal associationIncidenceOverall rateCancerSurveillanceProstatectomy
2012
Risk of more advanced cancer at surgery in African American men eligible for active surveillance.
Salmasi A, Han M, Kim I. Risk of more advanced cancer at surgery in African American men eligible for active surveillance. Journal Of Clinical Oncology 2012, 30: e15214-e15214. DOI: 10.1200/jco.2012.30.15_suppl.e15214.Peer-Reviewed Original ResearchActive surveillanceAdvanced cancerRadical prostatectomyProstate cancerNational Cancer InstituteAA menAfrican American menCaucasian manHigh riskCancer InstituteFavorable-risk prostate cancerPre-operative PSA levelLow-grade prostate cancerUnderwent radical prostatectomyRisk prostate cancerGrade prostate cancerJohns Hopkins Medical InstitutionsNCI criteriaPreoperative predictorsPSA levelsGrading of PCaPathological characteristicsSV involvementInclusion criteriaPositive cores
2011
Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Of Andrology 2011, 13: 838-41. PMID: 21785442, PMCID: PMC3739560, DOI: 10.1038/aja.2011.54.Peer-Reviewed Original ResearchConceptsActive surveillance criteriaActive surveillancePSA levelsSurveillance criteriaRadical prostatectomyLow-risk prostate cancerProstate-specific antigen levelRate of upstagingRisk of upstagingActive surveillance protocolsAcceptable treatment optionRisk of upgradingProportion of menNational Cancer InstituteCalifornia San FranciscoRisk of menContext of PSAPathological findingsAntigen levelsBiochemical recurrencePathological characteristicsSurveillance protocolTreatment optionsProstate cancerInclusion criteria